Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs VICI Properties Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while VICI Properties Inc trades at $26.1 (market cap $28.64B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and VICI Properties Inc pays a 6.92% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VICI | |
|---|---|---|
Market Cap | $39.89B | $28.64B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $33.93 |
52-Week Low | $278.09 | $25.94 |
Enterprise Value | $38.15B | $45.86B |
Dividend Yield | — | 6.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
VICI Properties trades at $26.01, showing modest daily gains. The stock is technically bearish with key support at $25, while fundamentals remain strong with a P/E of 8.91 and robust profitability margins. Recent news highlights concerns over tenant concentration but also underscores the REIT's investment-grade balance sheet and attractive 6.8% dividend yield. Q2 2026 earnings are anticipated on July 29, 2026.
The outlook is mixed: strong cash flows and analyst buy ratings support upside to a $30.75 target, but technical weakness and reliance on Caesars/MGM pose risks. Investors may find value in the discounted valuation if operational stability persists amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
